Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Testing in Breast Cancer: Assessing the Value of Repeated Centralized Testing in Excision Specimens

被引:2
|
作者
Hariri, Nosaibah [1 ]
Hasteh, Farnaz [1 ]
Walavalkar, Vighnesh [1 ]
Roma, Andres A. [1 ]
Fadare, Oluwole [1 ]
机构
[1] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA
关键词
repeat testing; estrogen receptor; progesterone receptor; human epidermal growth factor receptor-2; IN-SITU HYBRIDIZATION; INTRATUMORAL HETEROGENEITY; CORE-NEEDLE; CLINICAL ONCOLOGY/COLLEGE; PROTEIN EXPRESSION; AMERICAN SOCIETY; HER2; DISCORDANCE; ER; RECOMMENDATIONS;
D O I
10.1097/PAI.0000000000000525
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
At some tertiary breast care centers, where many patients are referred from other institutions, it is routine to repeat testing for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2/neu) in excision specimens if these tests were performed on the preceding biopsy at the referring facility. The goal of this study is to assess the value of this practice. We documented results from ER, PR, and HER2 testing in 541 consecutive invasive breast cancers excised over a 2.5-year period and analyzed the subset (n=153) for which testing was performed on the excision specimen solely due to the fact that testing on the preceding biopsy was performed at an outside institution. The rates and directions of biopsy-to-excision change were as follows: ER [1.3% (2/153), 100% from (+) to (-)]; PR [4% (6/153), 83% from (+) to (-)]; HER2/neu assessed by immunohistochemistry [21% (29/137)]; HER2/neu assessed by fluorescence in situ hybridization [3.3% (2/61); 50% from amplified to nonamplified and 50% vice versa]. There were no ER(-) and PR(-) biopsy cases that became ER and/or PR(+) in the excision. By coordinate analysis for the hormone receptors [ie, ER and/or PR(+) being indicative of "hormone receptor" (HR) positivity], there were no cases that changed from HR(+) in the biopsy to HR(-) in the excision (or vice versa), which suggests that repeat testing for ER and PR in this setting is of limited value. In an analysis that incorporated both immunohistochemistry and in situ fluorescence hybridization results, there were 2 cases with a clinically significant biopsy-to-excision change in HER2/neu status in which that change was detected primarily because the excision was retested. These findings provide baseline data for formulating policies on whether repeat testing should routinely be performed in the described scenario.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [41] Human Epidermal Growth Factor Receptor 2 Testing: Where Are We?
    De, Pradip
    Smith, Brian R.
    Leyland-Jones, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) : 4289 - 4292
  • [42] Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
    Abunada, Aya
    Sirhan, Zaid
    Thyagarajan, Anita
    Sahu, Ravi P.
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2023, 14 (05): : 198 - 202
  • [43] Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario
    Marshall, Deborah A.
    Ferrusi, Ilia L.
    Trudeau, Maureen
    Leighl, Natasha B.
    Hoch, Jeffrey S.
    Grazziotin, Luiza R.
    Khong, Hoa
    Pullenayegum, Eleanor
    Earle, Craig C.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (02) : 379 - 385
  • [44] NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry
    Allred, Craig
    Carlson, Robert W.
    Berry, Donald A.
    Burstein, Harold J.
    Edge, Stephen B.
    Goldstein, Lori J.
    Gown, Allen
    Hammond, M. Elizabeth
    Iglehart, James Dirk
    Moench, Susan
    Pierce, Lori J.
    Ravdin, Peter
    Schnitt, Stuart J.
    Wolff, Antonio C.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2009, 7 : S1 - S21
  • [45] Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China
    Zhu, Xinxin
    Ying, Jianming
    Wang, Fang
    Wang, Jie
    Yang, Hongying
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 147 (03) : 551 - 555
  • [46] Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China
    Xinxin Zhu
    Jianming Ying
    Fang Wang
    Jie Wang
    Hongying Yang
    Breast Cancer Research and Treatment, 2014, 147 : 551 - 555
  • [47] Breast cancer molecular subtypes defined by estrogen receptor progesterone receptor and human epidermal growth factor receptor type 2 status: Association with clinicopathologic parameters in Ivorian patients
    Effi, A.
    Arnim, N.
    Kour, B.
    Kofti, K.
    Traore, Z.
    Kouyate, M.
    VIRCHOWS ARCHIV, 2016, 469 : S63 - S63
  • [48] Reproductive Factors and Subtypes of Breast Cancer Defined by Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2: A Register-Based Study From Korea
    Lee, Jung Sun
    Oh, Minkyung
    CLINICAL BREAST CANCER, 2014, 14 (06) : 426 - 434
  • [49] A comparative analysis of body mass index with estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in pre- and postmenopausal breast cancer patients
    Chauhan, Richa
    Trivedi, Vinita
    Rani, Rita
    Singh, Usha
    JOURNAL OF MID-LIFE HEALTH, 2020, 11 (04) : 210 - 216
  • [50] Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2)
    van de Vijver, MJ
    EUROPEAN JOURNAL OF CANCER, 2001, 37 : S11 - S17